BostonGene Receives Frost & Sullivan’s 2026 Global Company of the Year for Advancing in AI-Driven Multimodal Oncology Platforms
Recognition highlights BostonGene's leadership in improving drug development decisions,reducing risk and accelerating patient…
Centrical Receives Frost & Sullivan’s 2026 Global Transformational Innovation Leadership Recognition for Excellence in Performance Intelligence
Recognized for advancing performance intelligence through transformational innovation that enhances frontline productivity,…
BIO-key Receives Notice of Non-Compliance from Nasdaq Related to Delay of its Form 10-K Filing
HOLMDEL, N.J., April 22, 2026 (GLOBE NEWSWIRE) -- BIO-key International, Inc. (Nasdaq: BKYI),…
Brigade Electronics Receives Frost & Sullivan’s 2026 European Market Leadership Recognition in the Commercial Vehicle Safety Systems Industry for Excellence in Fleet-Wide Safety Technology Standardization
Brigade Electronics is a leading hardware-centric supplier for leveraging safety regulations and…
Frost & Sullivan: Innovapptive Receives the 2026 Global Augmented Connected Worker, End-to-End Platforms Company of the Year Recognition for Excellence in AI-Powered Connected Worker Execution
Recognized for advancing platform development and enabling unified execution layer capabilities that…
Lumen Receives Frost & Sullivan’s 2026 North American Broadcast Video Managed Services Recognition for Excellence in Purpose-Built Broadcast Reliability and Operational Efficiency
Recognized for delivering purpose-built broadcast services that enhance operational efficiency, reliability, and…
MISTRAS Group Receives Frost & Sullivan’s 2026 Global NDT Field Inspection Services Company of the Year Recognition for Excellence in Integrated Asset Integrity and Digital Execution
MISTRAS Group delivers customer-centric asset integrity solutions that drive operational efficiency and…
Nxera Pharmas QUVIVIQ (daridorexant) 25mg and 50mg Receives Approval in Taiwan for the Treatment of Insomnia
Nxera’s partner Holling Bio-Pharma Corp. will commercialize QUVIVIQ® in Taiwan, a market with…
Mesoblast Receives IND Clearance From FDA to Directly Proceed to Registrational Trial for Approval of Ryoncil in Duchenne Muscular Dystrophy – CORRECTION
April 10, 2026 16:09 ET | Source: Mesoblast Limited Working with Parent…
Replimune Receives Complete Response Letter from the FDA for RP1 Biologics License Application for the Treatment of Advanced Melanoma
April 10, 2026 17:02 ET | Source: Replimune, Inc. WOBURN, Mass., April…
